Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Buy
65
IBIO Quote, Financials, Valuation and Earnings
Last price:
$1.68
Seasonality move
:
-0.26%
Day range:
$1.54 - $2.28
52-week range:
$0.56 - $6.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
73.81x
P/B ratio:
0.67x
Volume:
113.9M
Avg. volume:
5.8M
1-year change:
-39.71%
Market cap:
$37.6M
Revenue:
$400K
EPS (TTM):
-$1.39
Analysts' Opinion
-
Consensus RatingiBio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.72, iBio, Inc. has an estimated upside of 182.64% from its current price of $1.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.60 representing 4.19% downside risk from its current price of $1.67.
Fair Value
-
According to the consensus of 5 analysts, iBio, Inc. has 182.64% upside to fair value with a price target of $4.72 per share.
IBIO vs. S&P 500
-
Over the past 5 trading days, iBio, Inc. has overperformed the S&P 500 by 51.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
iBio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
iBio, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter iBio, Inc. reported revenues of $100K.
Earnings Growth
-
iBio, Inc. has grown year-over-year earnings for 11 quarters straight. In the most recent quarter iBio, Inc. reported earnings per share of -$0.11.
Enterprise value:
-8.7M
EV / Invested capital:
-0.15x
Price / LTM sales:
73.81x
EV / EBIT:
--
EV / Revenue:
-17.44x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$637K
Return On Assets:
-65.86%
Net Income Margin (TTM):
-4021.6%
Return On Equity:
-88.23%
Return On Invested Capital:
-75.48%
Operating Margin:
-5951%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $50K | $175K | $500K | -- | $100K | |
| Gross Profit | -$812K | -$1.1M | -$637K | -$278K | -$189K | |
| Operating Income | -$26.8M | -$15.6M | -$20.4M | -$4.1M | -$6M | |
| EBITDA | -$25.9M | -$14.4M | -$19.3M | -$3.8M | -$5.7M | |
| Diluted EPS | -$90.23 | -$6.64 | -$1.39 | -$0.46 | -$0.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $89.8M | $63.6M | $23M | $11.7M | $50.8M | |
| Total Assets | $143.7M | $84.6M | $37.7M | $24.5M | $64.2M | |
| Current Liabilities | $8.1M | $32.2M | $20.7M | $3.5M | $6M | |
| Total Liabilities | $43.2M | $36.2M | $24.5M | $6.8M | $8.1M | |
| Total Equity | $100.5M | $48.4M | $13.2M | $17.8M | $56M | |
| Total Debt | $35.6M | $4.3M | $3.6M | $4M | $2.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$21.8M | -$16.9M | -$17.3M | -$3.7M | -$5.7M | |
| Cash From Investing | $7M | $1.6M | -$21.5M | $713K | -$21.5M | |
| Cash From Financing | $3.7M | $21.9M | $55.8M | -$162K | $46.7M | |
| Free Cash Flow | -$25.1M | -$17.1M | -$17.3M | -$3.7M | -$5.7M | |
IBIO
Sector
Market Cap
$37.6M
$28.5M
Price % of 52-Week High
24.24%
51.43%
Dividend Yield
0%
0%
Shareholder Yield
-335.32%
-1.33%
1-Year Price Total Return
-39.71%
-21.18%
Beta (5-Year)
1.135
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.22
200-day SMA
Buy
Level
$1.49
Bollinger Bands (100)
Buy
Level
0.68 - 1.22
Chaikin Money Flow
Sell
Level
-122.6M
20-day SMA
Buy
Level
$1.18
Relative Strength Index (RSI14)
Buy
Level
66.96
ADX Line
Buy
Level
25.73
Williams %R
Neutral
Level
-46.2431
50-day SMA
Buy
Level
$1.14
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
196.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-21.4376)
Sell
CA Score
(Annual)
Level (-2.7843)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.5543)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, IBIO has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IBIO average analyst price target in the past 3 months is $4.72.
-
Where Will iBio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that iBio, Inc. share price will rise to $4.72 per share over the next 12 months.
-
What Do Analysts Say About iBio, Inc.?
Analysts are divided on their view about iBio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that iBio, Inc. is a Sell and believe this share price will drop from its current level to $1.60.
-
What Is iBio, Inc.'s Price Target?
The price target for iBio, Inc. over the next 1-year time period is forecast to be $4.72 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for iBio, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IBIO?
You can purchase shares of iBio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase iBio, Inc. shares.
-
What Is The iBio, Inc. Share Price Today?
iBio, Inc. was last trading at $1.68 per share. This represents the most recent stock quote for iBio, Inc.. Yesterday, iBio, Inc. closed at $1.67 per share.
-
How To Buy iBio, Inc. Stock Online?
In order to purchase iBio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IBIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IBIO
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
0.67x
1.82x
Price / LTM sales
73.81x
1.61x
Growth Metrics
IBIO
Sector
Revenue growth
14.29%
4.8%
Earnings growth
76.63%
11.11%
Revenue (5-year growth)
-24.57%
6.45%
Earnings forecast
-$0.07
-$0.20
Profitability
IBIO
Sector
Profitability FY 2025
-$726K
$3.6M
Return on invested capital
-75.48%
-31.15%
Return on assets
-65.86%
-27.72%
Return on equity
-88.23%
-36.72%
Earnings Date
Last Earnings Date
May
15
Next Earnings Date
Dec
9
Estimated Next Earnings Date
Mar
10
Balance Sheet
IBIO
Sector
Total cash
$49.6M
$27M
Short term investments
--
$25.7M
Total assets
$23.2M
$79.7M
Long term debt
$2.8M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is up 102.52% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
